These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15877679)

  • 1. Treatment for lupus nephritis: a revisit.
    Lai KN; Tang SC; Mok CC
    Nephrology (Carlton); 2005 Apr; 10(2):180-8. PubMed ID: 15877679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil in lupus glomerulonephritis.
    Mok CC; Lai KN
    Am J Kidney Dis; 2002 Sep; 40(3):447-57. PubMed ID: 12200794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options for resistant lupus nephritis.
    Mok CC
    Semin Arthritis Rheum; 2006 Oct; 36(2):71-81. PubMed ID: 16884971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?
    Boumpas DT; Sidiropoulos P; Bertsias G
    Nat Clin Pract Rheumatol; 2005 Nov; 1(1):22-30. PubMed ID: 16932624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
    Mok CC
    Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond immunosuppression - challenges in the clinical management of lupus nephritis.
    Masood S; Jayne D; Karim Y
    Lupus; 2009 Feb; 18(2):106-15. PubMed ID: 19151111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Con: Cyclophosphamide for the treatment of lupus nephritis.
    Mok CC
    Nephrol Dial Transplant; 2016 Jul; 31(7):1053-7. PubMed ID: 27190358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
    Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
    Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Kotb A; Wells GA
    Syst Rev; 2016 Sep; 5(1):155. PubMed ID: 27619512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide.
    Cunnane G; Chan OT; Cassafer G; Brindis S; Kaufman E; Yen TS; Daikh DI
    Arthritis Rheum; 2004 May; 50(5):1539-48. PubMed ID: 15146424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
    Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS
    Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of immunosuppressive drugs in the treatment of lupus nephritis.
    Klippel JH; Austin HA; Balow JE; leRiche NG; Steinberg AD; Plotz PH; Decker JL
    Rheum Dis Clin North Am; 1987 Apr; 13(1):47-56. PubMed ID: 3306824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
    Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
    Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
    Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
    J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
    Koo HS; Kim YC; Lee SW; Kim DK; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ
    Lupus; 2011 Nov; 20(13):1442-9. PubMed ID: 21951944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis?
    Paredes A
    Pediatr Nephrol; 2007 Aug; 22(8):1077-82. PubMed ID: 17370094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of lupus nephritis.
    Austin HA; Balow JE
    Semin Nephrol; 2000 May; 20(3):265-76. PubMed ID: 10855936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.